The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study
Abstract
OBJECTIVE: The increase in blood pressure that accompanies the obese state is almost invariably associated with alterations in metabolism (insulin resistance and dyslipidaemia) and the neurohumoral profile (activation of the renin-angiotensin system, sympathetic overactivity), which potentiate the cardiovascular risk associated with hypertension. However, debate remains as to the antihypertensive drug on which treatment of obesity-related hypertension should be based. The CROSS (Candesartan Role on Obesity and on Sympathetic System) study was undertaken to examine the antihypertensive, neuroadrenergic, and metabolic effects of an angiotensin II receptor blocker in comparison with a diuretic in obese hypertensive individuals. METHODS: In 127 obese hypertensive individuals aged 50.7 +/- 5.1 years (mean +/- SD), we measured clinic blood pressure, heart rate, plasma glucose, and insulin at rest and during an oral glucose load before and 12 weeks after treatment with either candesartan cilexetil (8-16 mg once daily) or hydrochlorothiazide (HCTZ, 25-50 mg once daily), administered orally in accordance with a double-blind, randomized, placebo-controlled, two-parallel-groups study design. Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin. In a subgroup of patients, measurements also included direct microneurographic recording of muscle sympathetic nerve activity (MSNA) in the peroneal nerve. RESULTS: Candesartan cilexetil caused a significant (P < 0.01) reduction in both mean blood pressure (from 114.2 +/- 5.1 to 99.6 +/- 6.0 mmHg) and MSNA (from 51.0 +/- 12.3 to 40.4 +/- 12.5 bursts per 100 heart beats), and a significant (P < 0.02) increase in insulin sensitivity (AUC IRI: from -23.2 +/- 22.1 to -17.6 +/- 12.2). In contrast, HCTZ did not significantly affect MSNA and worsened insulin sensitivity, while achieving blood pressure reductions similar to those produced by candesartan cilexetil. CONCLUSIONS: These data provide evidence that, in obese hypertensive individuals, treatment with candesartan cilexetil has an antihypertensive effect similar to that of HCTZ. Unlike diuretic treatment, however, treatment with candesartan cilexetil improves insulin sensitivity and exerts sympathoinhibitory effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As mentioned above, blockade of the RAAS with AngII receptor blockers, angiotensin-converting enzyme (ACE) inhibitors or renin inhibitors reduces BP in patients with obesity and hypertension64–66.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [65]
In the citing paper
“Therefore, although we cannot completely exclude an effect of medications in our 2 hypertensive groups, they could not have entirely caused the excessive sympathetic hyperactivity.”
From Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension (2004) · cites this paper as [23]
In the citing paper
“Although we cannot entirely exclude some influence of these agents, it is known in hypertensive patients that chronic ACE inhibitor therapy does not affect MSNA levels, 22 ARBs may decrease it, 23 and -blockers may have no effect or decrease MSNA.24,25”
From Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension (2004) · cites this paper as [23]
In the citing paper
“In obese hypertensive subjects, chronic hydrochlorothiazide therapy that lowers arterial pressure did not significantly affect MSNA levels.23”
From Sympathetic Neural Activation in Nondiabetic Metabolic Syndrome and Its Further Augmentation by Hypertension (2004) · cites this paper as [23]
Citations
Cites
Kopelman, P. G. (2000) · Nature · doi:10.1038/35007508 · Cited by 4,795
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,345
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699
Insulin resistance and cardiovascular disease
Ginsberg, H. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10762 · Cited by 1,372
Cardiovascular protection and blood pressure reduction: a meta-analysis
Staessen, J. A., Wang, J., & Thijs, L. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06411-x · Cited by 939
The Relation of Adiposity to Blood Pressure and Development of Hypertension
Kannel, W. B., BRAND, N., SKINNER, J. J., Dawber, T. R., & MCNAMARA, P. M. (1967) · Annals of Internal Medicine · doi:10.7326/0003-4819-67-1-48 · Cited by 815
Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions
Esler, M., Jennings, G., Lambert, G., Meredith, I., Horne, M., & Eisenhofer, G. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.4.963 · Cited by 794
Sympathetic Activation in Obese Normotensive Subjects
Grassi, G., Seravalle, G., Cattaneo, B. M., Bolla, G. B., Lanfranchi, A., Colombo, M., Giannattasio, C., Brunani, A., Cavagnini, F., & Mancia, G. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.560 · Cited by 614
Self-citationYu-Poth, S., Zhao, G., Etherton, T., Naglak, M., Jonnalagadda, S., & Kris-Etherton, P. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.4.632 · Cited by 584
Research works printed but not linked: 2
- 1998, Obes Res, 6, 71S
- Mancia, 1998, J Hypertens, 16, S35
Cited by
Sorted by citations
Items 101–200 of 224
Huang, G.-Z., Tang, Y., Wang, B., Zhang, B., Hu, T.-J., Zhang, L., Zhang, X., & Yuan, Ž. (2011) · Saudi Medical Journal · doi:10.15537/1658-3175.5393 · Cited by 25
Sympathoinhibition by Atorvastatin in Hypertensive Patients
Gomes, M. E. R., Tack, C. J., Verheugt, F. W. A., Smits, P., & Lenders, J. W. M. (2010) · Circulation Journal · doi:10.1253/circj.cj-10-0427 · Cited by 24
Francica, J. V., Bigongiari, A., Mochizuki, L., Scapini, K., Moraes, O. A., Mostarda, C., Caperuto, É., Irigoyen, M., de Angelis, K., & Rodrigues, B. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0099-9 · Cited by 22
Fogari, R., Preti, P. S., Zoppi, A., Mugellini, A., Corradi, L., Lazzari, P., Santoro, T., & Derosa, G. (2008) · Internal Medicine · doi:10.2169/internalmedicine.47.1427 · Cited by 24
Tomiyama, H., Motobe, K., ZAYDUN, G., Koji, Y., Yambe, M., Arai, T., Kushiro, T., & Yamashina, A. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.033 · Cited by 24
Critical evaluation of the efficacy and tolerability of azilsartan
Caterina, A. D., Harper, A. R., & Cuculi (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22589 · Cited by 22
Resistant or Refractory Hypertension: Are They Different?
Modolo, R., de Faria, A. P., Almeida, A. R., & Moreno, H. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0485-1 · Cited by 22
Elevations in Serum Creatinine Concentration: Concerning or Reassuring?
Epstein, B. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.6.697.34731 · Cited by 22
Metabolic effects of cardiovascular drugs
Fragasso, G., Margonato, A., Spoladore, R., & Lopaschuk, G. D. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.08.001 · Cited by 21
Papademetriou, V. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.08.063 · Cited by 21
Morganti, A. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110964 · Cited by 21
Bariatric surgery for morbid obesity: risks and benefits in chronic kidney disease patients.
Zalesin, K., & McCullough, P. (2006) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2006.07.008 · Cited by 22
Selective Deletion of Renin-b in the Brain Alters Drinking and Metabolism
Shinohara, K., Nakagawa, P., Gomez, J. A., Morgan, D. A., Littlejohn, N. K., Folchert, M. D., Weidemann, B. J., Liu, X., Walsh, S. A., Ponto, L. L. B., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09923 · Cited by 20
Neural mechanisms and management of obesity-related hypertension
Esler, M., Eikelis, N., Lambert, É., & Straznicky, N. E. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0072-7 · Cited by 20
Jacob, S., & Henriksen, E. J. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03704.x · Cited by 20
Okada, Y., Jarvis, S. S., Best, S. A., Bivens, T. B., ADAMS-HUET, B. A., Levine, B. D., & Fu, Q. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.261362 · Cited by 19
Gomes, M. E. R., Aengevaeren, W. R. M., Lenders, J. W. M., Verheugt, F. W. A., Smits, P., & Tack, C. J. (2010) · Clinical Cardiology · doi:10.1002/clc.20676 · Cited by 19
The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients
Meyers, K. E. C., Lieberman, K. V., Solar‐Yohay, S., Han, G., & Shi, V. C. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00502.x · Cited by 19
Seravalle, G., & Grassi, G. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-62491-9_5 · Cited by 22
Self-citationManagement of arterial hypertension in obese patients
Wenzel, U. O., & Krebs, C. F. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0090-7 · Cited by 17
Drug Mechanisms to Help in Managing Resistant Hypertension in Obesity
Jansen, P. M., Danser, J., Spiering, W., & van den Meiracker, A. H. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0123-5 · Cited by 17
Pathophysiology of Obesity—Induced Hypertension and Target Organ Damage
Hall, J. E., da Silva, A. A., Brandon, E. L., Stec, D. E., Ying, Z., & Jones, D. W. (2007) · Elsevier eBooks · doi:10.1016/b978-0-323-03961-1.50041-6 · Cited by 18
Body fat change and 8‐year incidence of hypertension: Korean Genome and Epidemiology Study
Lee, S.-B., Cho, A., Kwon, Y.-J., & Jung, D. (2019) · The Journal of Clinical Hypertension · doi:10.1111/jch.13723 · Cited by 13
Dell’Omo, G., Penno, G., Prato, S. D., & Pedrinelli, R. (2005) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840501000406 · Cited by 17
Treatment of Arterial Hypertension in Obese Patients
Wenzel, U. O., Benndorf, R. A., & Lange, S. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.009 · Cited by 18
Hypertension treatment update: Focus on direct renin inhibition
Fitzgerald, M. A. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00589.x · Cited by 17
Hipertensión arterial y síndrome metabólico
Otero, M. L., & Claros, N. M. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)75336-1 · Cited by 20
The complex role of PPARγ in renal dysfunction in obesity: Managing a Janus-faced receptor
Dobrian, A. D. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.01.017 · Cited by 16
Hyperinsulinemic rats are normotensive but sensitized to angiotensin II
Johansson, M. E., Andersson, I. J., Alexanderson, C., Skøtt, O., Holmäng, A. B., & Bergström, G. M. L. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00493.2007 · Cited by 15
Blood Pressure Lowering Effects of Rimonabant in Obesity‐related Hypertension
Grassi, G. M., Quarti‐Trevano, F., Seravalle, G., Arenare, F., Brambilla, G., & Mancia, G. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01688.x · Cited by 15
Self-citationCandesartan cilexetil in cardiovascular disease
Ross, A., & Papademetriou, V. (2004) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2.6.829 · Cited by 15
Ferreira, M. J., Silva, M. P. D. S. F., Dias, D. D. S., Bernardes, N., Irigoyen, M. C., & Angelis, K. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289715 · Cited by 14
Failure of Antihypertensive Treatment to Restore Normal Sympathetic Activity
Quarti‐Trevano, F., Seravalle, G., Facchetti, R., Tsioufis, K. P., Dimitriadis, K. S., Manta, E., Mancia, G., & Grassi, G. M. (2025) · Hypertension · doi:10.1161/hypertensionaha.124.24429 · Cited by 14
Self-citationJemtel, T. H. L., Richardson, W., Samson, R., Jaiswal, A., & Oparil, S. (2017) · Current Hypertension Reports · doi:10.1007/s11906-017-0713-6 · Cited by 14
Heusser, K., Tank, J., Diedrich, A., Fischer, A., Heise, T., & Jordan, J. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.08.036 · Cited by 14
A review of chemical therapies for treating diabetic hypertension
Sarafidis, P. A., Alexandrou, M. E., & Ruilope, L. M. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1328054 · Cited by 13
Pathophysiologic therapeutic targets in hypertension: a cardiological point of view
Fragasso, G., Maranta, F., Montanaro, C., Salerno, A., Torlasco, C., & Margonato, A. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.655724 · Cited by 14
Huang, S., Wu, T.-C., Lin, S., & Chen, J. (2009) · Circulation Journal · doi:10.1253/circj.cj-09-0387 · Cited by 13
Managing cardiovascular risk in patients with metabolic syndrome
Bassand, J. (2006) · Clinical cornerstone · doi:10.1016/s1098-3597(06)80003-7 · Cited by 14
Assessment of cardiovascular risk and choice of antihypertensive therapy
Kannel, W. B., & Vasan, R. S. (2004) · Current Hypertension Reports · doi:10.1007/s11906-004-0052-2 · Cited by 12
Multimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system
Paton, J. F. R., Żera, T., Vadigepalli, R., Herring, N., & Paterson, D. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01212-4 · Cited by 16
From pathophysiology to novel approaches for obesity-associated hypertension
Kanbay, M., Yayci, E., Genc, C., Çöpür, S., Aktaş, Ö. Y., Sarafidis, P. A., Covic, A. C., Ortíz, A., & Laffin, L. J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf218 · Cited by 10
Zhang, J., Tian, L., & Guo, L. (2019) · Journal of International Medical Research · doi:10.1177/0300060519868337 · Cited by 10
Maranta, F., Spoladore, R., & Fragasso, G. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_169 · Cited by 11
Dendorfer, A., Dominiak, P., Tempel, K., & Raasch, W. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000179510.86265.63 · Cited by 9
Feeling the pressure: (patho) physiological mechanisms of weight gain and weight loss in humans
Middlemiss, J. E., & McEniery, C. M. (2016) · Hypertension Research · doi:10.1038/hr.2016.142 · Cited by 9
Hu, Y., Bao, J., Gao, Z., Ye, L., & Wang, L. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s446904 · Cited by 9
Role of antidiabetic agents in type 2 diabetes patients with chronic kidney disease
Lin, W.-R., Liu, K., Ling, T., Wang, M., & Lin, W. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.352 · Cited by 8
Recommendations for Special Populations
Tan, A. S., Kuppuswamy, S., Whaley‐Connell, A. T., Kurukulasuriya, L. R., & Sowers, J. R. (2004) · The Endocrinologist · doi:10.1097/01.ten.0000146262.10013.e7 · Cited by 8
Antihypertensive therapy in the obese hypertensive patient
Chrostowska, M., Szczęch, R., & Narkiewicz, K. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000242173.14082.dc · Cited by 8
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_9 · Cited by 9
Obesity-Associated Hypertension
Uwaifo, G. I. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_13 · Cited by 7
Parhofer, K. G., Birkeland, K. I., DeFronzo, R. A., Prato, S. D., Bhaumik, A., & Ptaszynska, A. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02246.x · Cited by 7
Grassi, G. M., Quarti‐Trevano, F., Scopelliti, F., Seravalle, G., Cuspidi, C., & Mancia, G. (2006) · Blood Pressure · doi:10.1080/08037050600963669 · Cited by 7
Self-citationVase, H. Ø., Lauridsen, T. G., Bech, J. N., & Pedersen, E. B. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03149.x · Cited by 7
Treatment of Arterial Hypertension in Obese Patients
Wenzel, U. O., & Krebs, C. F. (2006) · KARGER eBooks · doi:10.1159/000095333 · Cited by 7
Renal Denervation for Drug-Resistant Hypertension: Suffering Its Original Sin, Seeking Redemption
Floras, J. S. (2014) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2014.02.008 · Cited by 6
Identifying treatment response to antihypertensives in patients with obesity-related hypertension
Schrover, I. M., Dorresteijn, J. A. N., Smits, J. E., Danser, A. H. J., Visseren, F. L. J., & Spiering, W. (2017) · Clinical Hypertension · doi:10.1186/s40885-017-0077-x · Cited by 6
Position of fixed‐dose combinations containing an AT1‐receptor blocker and a thiazide diuretic
Waeber, B. (2005) · Blood Pressure · doi:10.1080/08037050500390534 · Cited by 6
Yan, W., Pan, C., Dou, J., MENG, J.-H., Wang, B., & Mu, Y. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3297 · Cited by 6
Role of Sympathetic Nervous System in the Metabolic Syndrome and Sleep Apnea
Seravalle, G., & Grassi, G. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-420168-2.00018-1 · Cited by 5
Self-citationSympathetic Responses to Antihypertensive Treatment Strategies
Dell’Oro, R., Quarti‐Trevano, F., Ambrosino, P., & Grassi, G. M. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01339-2 · Cited by 5
Self-citation50 Years of Thiazides: Should Thiazide Diuretics Be Considered Third-Line Hypertension Treatment?
Brown, A. L., & Captain, B. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181e90863 · Cited by 5
Resistant hypertension: a volemic or nervous matter?
Modolo, R., de Faria, A. P., & Moreno, H. (2015) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2015.01.014 · Cited by 5
Visceral Fat and Hypertension: Sex Differences
Pausová, Z. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00009-x · Cited by 5
High dose ascorbic acid does not reverse central sympathetic overactivity in chronic heart failure
Gomes, M. E., Messaoudi, S. E., Lenders, J. W. M., Bellersen, L., Verheugt, F. W. A., Smits, P., & Tack, C. J. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01205.x · Cited by 5
Aksnes, T. A., Flaa, A., Sevre, K., Mundal, H. H., Rostrup, M., & Kjeldsen, S. E. (2008) · Blood Pressure · doi:10.1080/08037050802162847 · Cited by 5
Erectile Dysfunction in Coronary Artery Disease and Heart Failure
Gandaglia, G., Briganti, A., Montorsi, P., Montorsi, F., & Vlachopoulos, C. V. (2014) · Springer eBooks · doi:10.1007/978-3-319-08272-1_7 · Cited by 4
Blood pressure and cardiorenal responses to antihypertensive therapy in obese women
Rosa, E. C., Zanella, M. T., Kohlmann, N. E. B., Ferreira, S. R. G., Plavnik, F. L., Ribeiro, A. B., & Kohlmann, O. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000100010 · Cited by 4
Inhibiting the renin–angiotensin system: Why and in which patients
Berra, K. A., & Miller, N. H. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2008.00374.x · Cited by 4
Waeber, B., Brunner, H.-R., Burnier, M., & Cohn, J. N. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_89 · Cited by 4
Pathophysiology of Type 2 Diabetes
Kesavadev, J., Jawad, F., Deeb, A., Coetzee, A., Ansari, M., Shrestha, D., Somasundaram, N. P., & Kalra, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_8 · Cited by 3
Amin, S. N., Abdalgeleel, S. A., Al‐Gahtany, M., Shaltout, S. A., Gazzar, W. B. E., & Elberry, D. A. (2021) · Brain Sciences · doi:10.3390/brainsci11050644 · Cited by 3
A modern view on the prevention and treatment of arterial hypertension in obesity
Молчанова, О. В. (2021) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20212406197 · Cited by 3
do Carmo, J. M., da Silva, A. A., & Hall, J. E. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa170 · Cited by 3
Pathophysiology and Optimal Management of Hypertension in Patients with Cardiometabolic Syndrome
Ihm, S. (2021) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2021.1.e3 · Cited by 3
Nishihara, M., Hirooka, Y., & Sunagawa, K. (2014) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2014.897719 · Cited by 3
Plosker, G. L., & Keam, S. J. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624120-00008 · Cited by 3
The Sympatho-Adrenal System in the Metabolic Syndrome
Landsberg, L. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-116-5_6 · Cited by 3
Villecco, A., Cocci, C., & Emidio, M. D. (2004) · Current Therapeutic Research · doi:10.1016/s0011-393x(04)90031-8 · Cited by 3
Involvement of Renal Sympathetic Nerve in Pathogenesis of Hypertension
Kumagai, H., Onami, T., Iigaya, K., Takimoto, C., Imai, M., Matsuura, T., Sakata, K., Oshima, N., Hayashi, K., & Saruta, T. (2004) · KARGER eBooks · doi:10.1159/000078710 · Cited by 3
Renin-Angiotensin-Aldosterone System in Diabetic Cardiovascular Complications
Balakrishnan, V. S. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_31 · Cited by 2
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7380-0_5 · Cited by 2
ROLE OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) IN OBESITY-ASSOCIATED HYPERTENSION
Gupte, M. (2011) · UKnowledge (University of Kentucky) · Cited by 2
Трухан, Д. И. (2014) · Systemic Hypertension · doi:10.26442/sg29031 · Cited by 2
Adipose Tissue and Blood Pressure Regulation
Cassis, L. A., & Police, S. B. (2010) · Wiley eBooks · doi:10.1002/9783527629527.ch13 · Cited by 2
The Renin—Angiotensin System in Diabetic Cardiovascular Complications
Feener, E. P. (2005) · Humana Press eBooks · doi:10.1385/1-59259-908-7:073 · Cited by 2
Obesity, Diabetes, and Hypertension
Tan, A. S., Brietzke, S., Gardner, D. W., & Sowers, J. R. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-985-1_10 · Cited by 2
Pourdjabbar, A., Parker, T. G., Desjardins, J., Nguyen, Q. T., Tsoporis, J. N., Lapointe, N., & Rouleau, J. L. (2005) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y05-072 · Cited by 2
Dobrescu, M., Păun, D. L., Buculei, S., Ghimigean, A., & Poiană, C. (2022) · Internal Medicine · doi:10.2478/inmed-2022-0199 · Cited by 1
Grassi, G. M., Facchetti, R., Jelaković, A., & Cuspidi, C. (2026) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-026-00786-5 · Cited by 1
Self-citationBramlage, P., Buhck, H., & Zemmrich, C. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0169-2 · Cited by 1
Sympathetic and Renin–Angiotensin Activity in the Pathophysiology of Hypertension
Covic, A. C., & Segall, L. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_35 · Cited by 1
Pi-Sunyer, X., & Kokkoris, P. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3053-9.50037-8 · Cited by 1
Obesity, adipokines and their relationship with insulin resistance
García-Ortega, W. A., Angulo-Camacho, J. Á., & Ibarra-Sánchez, A. (2023) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v6i6.4335 · Cited by 1
Angiotensin Converting Enzyme Inhibitors and AT1 Antagonists for Treatment of Hypertension
Morisco, C., & Trimarco, B. (2014) · Springer eBooks · doi:10.1007/978-3-319-09788-6_1 · Cited by 1
Hipertensión arterial y síndrome metabólico
Caro, J. L. L., & Otero, M. L. (2006) · Medicina de Familia SEMERGEN · doi:10.1016/s1138-3593(06)73224-5 · Cited by 1
Central Control of Sympathetic and Renin Angiotensin System in the Development of Hypertension
Ganguly, P. K., Almiro, A., Dawalibi, A., Mahayni, T. A., & Mohammad, K. S. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-14952-8_11 · Cited by 1
Sympathetic vascular tone in human obesity
Correia, M. (2007) · doi:10.17077/etd.v54kf0if · Cited by 1
Assessment of 24-h neuroadrenergic profile: does the dream come true?
Grassi, G. M. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000170375.15838.e3 · Cited by 1
Self-citation
Metadata
- Authors
- Grassi, G., Seravalle, G., Dell'Oro, R., Trevano, F. Q., Bombelli, M., Scopelliti, F., Facchini, A., & Mancia, G.
- Affiliations
- IRCCS Istituto Auxologico Italiano (IT)
- University of Milano-Bicocca (IT)
- Azienda Ospedaliera San Gerardo (IT)
- Corresponding author
- Mancia, Giuseppe
- Venue
- Journal of Hypertension
- Published
- 2003-09
- Volume
- 21
- Issue
- 9
- Pages
- 1761-1769
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2007653610
- Cited by
- 225
- References
- 40
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 4 · 2023: 9 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 8 · 2018: 2 · 2017: 9 · 2016: 10 · 2015: 12 · 2014: 13 · 2013: 5 · 2012: 12
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- candesartan cilexetil, hydrochlorothiazide, obesity-related hypertension, angiotensin receptor blockers, diuretics, insulin resistance, insulin sensitivity, muscle sympathetic nerve activity, sympathetic nervous system, blood pressure reduction, renin-angiotensin system, antihypertensive drug comparison, microneurography, oral glucose tolerance test
- MeSH terms
- Adolescent, Adult, Aged, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Blood Glucose, Blood Pressure, Female, Humans, Hydrochlorothiazide, Hypertension, Insulin Resistance, Male, Middle Aged, Obesity, Sympathetic Nervous System, Tetrazoles, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
